|
[18F]Florbetaben Clinical Trials
6 actively recruiting trials across 3 locations
Also known as: Neuraceq, [18F] Florbetaben
Pipeline
Phase 1: 2Phase 2: 2Phase 3: 1
Top Sponsors
- National Institute of Mental Health (NIMH)2
- Patrick Lao1
- Life Molecular Imaging GmbH1
- Fondazione IRCCS Policlinico San Matteo di Pavia1
- Columbia University1
Indications
- Alzheimer's Disease4
- Heart Disease2
- AL Amyloidosis2
- Mild Cognitive Impairment2
- Alzheimer Disease2
Bethesda, Maryland2 trials
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
National Institutes of Health Clinical Center
Phase 1
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
National Institutes of Health Clinical Center
Phase 1
New York, New York2 trials
Discovery and Validation of Genetic Variants Affecting Microglial Activation in Alzheimer's Disease
Columbia University Irving Medical Center
Phase 2
Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease
Columbia University Irving Medical Center
Phase 2
Other1 trial
Kansas City, Kansas1 trial
Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis
St Luke's Hospital
Phase 3
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.